Kansas PKD Research and Translation Core Center
School of Medicine > Kidney Institute > PKD Center > Clinical Research Core > Clinical trials in PKD at KUMC
Clinical trials in PKD at KUMC
Clinical trials in PKD currently ongoing at KUMC:
Observational studies
| Trial name | Sponsor | Summary | Details | Status |
Study coordinator |
| PKD Biomarkers Repository Study | NIH | Identification of reliable biological markers of cyst growth in early stages of PKD More at: www.kumc.edu/pkdstudy |
• Length: Five years • Time commitment: Two hours once per year • Procedures: MRI, blood and urine labs, and questionnaires • Eligibility: children and young adults age 35 and younger, who are diagnosed with PKD and have normal kidney function |
Recruiting | Cathy Creed Debbie Griffin |
| KUMC PKD Repository | KU Kidney Institue/PKD Foundation | Collection of blood and urine from individuals with PKD are made available to investigators involved in PKD research | • Length: One visit only • Time commitment: One hour or less • Procedures: Collection of blood and urine, and brief medical history questionnaire •Eligibility: age 2 - 70, diagnosed with PKD |
Recruiting | Cathy Creed |
| CRISP IV | NIH/NIDDK | Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) IV: Prognosis for End-Stage Renal Disease and Biomarker Validation |
• Length: 4 years · Time commitment: One in person enrollment visit- 1 hour • Four blood draws - 30 min visit to a lab • Four imes a year- 30 min visit by telephone or email · Procedures: Blood labs, Medical history, and Questionnaires •Eligibility: Participated in the past CRISP studies and have not reached end stage renal disease (ESRD) or participated in the HALT-PKD study
|
Active Enrollment limited to those who were previously enrolled in CRISP study |
|
| PKD Registry | NIH | Collect and store medical information in a PKD database used by investigators at KUMC to assess feasibility when developing new PKD studies and to recruit for future trials |
• Length: Indefinitely · Time commitment: 30 min visit (may be over the phone) · Procedures: Questionnaire |
Active and enrolling |
Studies involving drug therapy
| Trial name | Sponsor | Summary | Details | Status |
Study coordinator |
| Otuska 211 | Otsuka | Open label extension study to evaluate the long term safety of Tolvaptan in patients with PKD | • Length: 30 months with visits every 3 months • Time commitment: One hour each visit • Procedures: Medication, labs, and questionnaires • Eligibility: Completed and transfered from Otsuka 210, 271, or prior tolvaptan ADPKD trial |
Active | Debbie Griffin |
| PKD Hydralazine study | Frontiers |
Hydralazine which is an FDA approved medication, has been shown to reduce cyst growth in mice. The study will determine if low dose Hydralazine is an effective, affordable, and safe treatment for PKD. |
• Length: 8 weeks |
Active |
Debbie Griffin |